- 期刊
A Prospective Study of Hepatitis during Antituberculous Treatment in Taiwanese Patients and a Review of the Literature
並列摘要
Background/Purpose: The present study prospectively investigated the incidence of and factors associated with hepatitis during antituberculous treatment in patients with tuberculosis and various underlying diseases. The results were compared with those of previously published studies. Methods: Patients treated with antituberculous agents were enrolled from July 1, 2000 to July 31, 2001, in the divisions of chest and infectious diseases at National Taiwan University Hospital and followed until November 30, 2001. Hepatitis was defined as an aminotransferase level ＞ 5 times the upper limit of normal (ULN), or ＞ 3 times ULN in the presence of symptoms of hepatitis, or total bilirubin level ＞ 3 mg/dL. Studies reporting the incidence of hepatitis during antituberculous treatment were reviewed for comparison. Results: Among 261 patients, median age was 58 years (range, 17-90 years), 17.7% had abnormal baseline liver function tests and 18.4% had concurrent hepatotoxic drug use. Fifteen patients (5.7%) had hepatitis B virus infection, 17 (6.5%) had hepatitis C virus infection, 14 (5.4%) had liver cirrhosis, and 15 (5.7%) had human immunodeficiency virus infection. Hepatitis occurred in 42 patients (16.1%), with 60% of the events in the first 2 months of treatment. Such an incidence was comparable to that in other Asian countries (5.3-18.2%) and slightly higher than that in Western countries (2.4-19%). In multivariate analysis, abnormal liver function tests at baseline and liver cirrhosis were independent factors for development of hepatitis. Conclusion: Elevation of liver function tests was not uncommon during antituberculous treatment, especially in the first 2 months. Patients with abnormal liver function tests at baseline or liver cirrhosis should be closely monitored.
延伸閱讀
- 邱冠霆、林民浩、邱珠敏、周玉民、楊靖慧（2019）。Incidence and Risk Factors of Acute Hepatitis B in Hepatitis B Virus Vaccinated Birth Cohorts in Taiwan。台灣醫學，23(1)，1-9。https://doi.org/10.6320/FJM.201901_23(1).0001
- 邱珠敏、孫芝佩、周玉民、楊靖慧（2017）。Epidemiology and Prevention Strategies of Hepatitis C in Taiwan。台灣醫學，21(6)，582-588。https://doi.org/10.6320/FJM.201711_21(6).0004
- Sung, J. L., Chen, D. S., Lai, M. Y., Yu, J. Y., Wang, T. H., Wang, C. Y., 楊鼎勳, Lee, C. Y., Chen, S. H., & Ko, T. M. (1984). Epidemiological Study on Hepatitis B Virus infection in Taiwan. 中華民國消化系醫學會雜誌, 1(1), 1-9. https://doi.org/10.6557/GJTa.198401_1(1).0001
- Lee, M. H. (2010). Epidemiology and Health Risk Assessment of Hepatitis C Virus Infection in Taiwan [doctoral dissertation, National Taiwan University]. Airiti Library. https://doi.org/10.6342/NTU.2010.00220
- 黃凱琳、游山林、王秋華、朱健次、楊照雄、陳建仁（1992）。Seroepidemiology of Hepatitis C Virus among Residents of an Aboriginal Township in Southern Taiwan。中華民國公共衛生學會雜誌，11(2)，124-130。https://doi.org/10.6288/JNPHARC1992-11-02-05